Serina Therapeutics, Inc. (NASDAQ: SER) reported insider activity by its Chief Scientific Officer, Randall Moreadith, who on February 2, 2026 sold 6,500 shares of common stock. The sale generated proceeds totaling $19,680, with trade prices recorded between $3.00 and $3.05 per share.
On the same date, Moreadith exercised options to acquire an additional 6,500 shares of the companys common stock at an exercise price of $0.06 per share, for a total exercise cost of $390. Those options were fully vested and exercisable and originated from a stock option grant that carries an expiration date of May 6, 2031.
Separately, Serina Therapeutics announced regulatory progress for its lead candidate, SER-252. The company received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for SER-252, which targets advanced Parkinsons disease. With that clearance in hand, Serina is cleared to begin the planned Phase 1b clinical study. The company said site-level activities are already underway in Australia to support the broader global program.
On the corporate and financial front, Serina disclosed that the New York Stock Exchange has notified the company of a listing deficiency. The notice relates to the companys failure to meet certain equity standards, reflecting stockholders equity of $1.6 million and reported losses in three of the last four fiscal years.
In governance developments, at Serinas 2025 Annual Meeting of Stockholders the company announced the election of Steve Ledger and Karen J. Wilson to its board of directors. Both directors received substantial shareholder support and will serve until the 2028 Annual Meeting or until their successors are duly appointed.
Taken together, the transactions and corporate updates mark a period of activity for Serina across multiple fronts - insider transactions and option exercises, regulatory advancement for its clinical program, a listing deficiency notice tied to limited equity and historical losses, and board refreshment through recent elections.